SAM
APLS

S.A. Mason’s Apellis Pharmaceuticals APLS Stock Holding History

S.A. Mason’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-925
Closed -$61K – 314
2023
Q2 		$61K Hold
925
– – 0.04% 238
2023
Q1 		$61K Sell
925
-1,435
-61% -$82.8K 0.04% 238
2022
Q4 		$122K Hold
2,360
– – 0.09% 180
2022
Q3 		$161K Sell
2,360
-800
-25% -$47.3K 0.13% 166
2022
Q2 		$143K Buy
3,160
+415
+15% +$18.9K 0.1% 175
2022
Q1 		$139K Sell
2,745
-1,410
-34% -$62.2K 0.09% 187
2021
Q4 		$196K Hold
4,155
– – 0.12% 161
2021
Q3 		$137K Buy
4,155
+3,445
+485% +$194K 0.09% 177
2021
Q2 		$45K Buy
+710
New +$36.6K 0.03% 254

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

S.A. Mason's APLS Position: Q3 2023 in Review

S.A. Mason sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 925 shares — an estimated $61K sold.

S.A. Mason first reported a position in APLS in Q2 2021 and held it in 9 quarters. The position peaked at $196K in Q4 2021. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

  • S.A. Mason reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • S.A. Mason sold 925 Apellis Pharmaceuticals shares in Q3 2023, an estimated $61K.
  • S.A. Mason first reported a position in Apellis Pharmaceuticals in Q2 2021 and held it in 9 quarters.
  • S.A. Mason's Apellis Pharmaceuticals position peaked at $196K in Q4 2021.
  • 256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on S.A. Mason's 13F filing for Q3 2023, filed 13 Oct 2023.